BACKGROUND: We analyzed the inodilator properties of levosimendan in patients with chronic heart failure and severe functional mitral regurgitation. METHODS: We studied 20 patients under optimal treatment and in stable clinical condition (New York Heart Association 3.19 ± 0.66; 70 ± 7 years). Levosimendan was infused as a bolus (12 μg/kg in 10 min) followed by a 24-h infusion (0.1-0.2 μg/kg per min). Before and after infusion, Doppler echocardiography, brain natriuretic peptide determination and noninvasive hemodynamic monitoring with bioimpedance cardiography were performed. RESULTS: Levosimendan improved left ventricular ejection fraction (ejection fraction 31 ± 4 from 27 ± 4, P < 0.05), decreased brain natriuretic peptide (333 ± 139 from 629 ± 63 pg/ml, P < 0.01), reduced mitral valve effective regurgitant orifice area to 27 ± 5 from 36 ± 7 mm (P < 0.01) and the velocity of displacement of mitral annulus [ratio between E and E′ waves on Doppler and tissue Doppler (E/E′) from 22.7 ± 1.6 to 13.1 ± 0.6, P < 0.01]. Noninvasive hemodynamic monitoring showed increased acceleration index (a marker of inotropism), and reduced peripheral resistances and thoracic fluid content (P < 0.01). After 4 weeks of washout, some of these effects were still evident. CONCLUSION: In patients with chronic heart failure and functional mitral regurgitation, levosimendan acutely improved systolic and diastolic function, reduced mitral regurgitation and modulated neurohormonal activation, with a tendency for these changes to persist over a short-term follow-up. © 2010 Italian Federation of Cardiology.

Branzi, G., Malfatto, G., Villani, A., Ciambellotti, F., Revera, M., Giglio, A., et al. (2010). Acute effects of levosimendan on mitral regurgitation and diastolic function in patients with advanced chronic heart failure. JOURNAL OF CARDIOVASCULAR MEDICINE, 11(9), 662-668 [10.2459/JCM.0b013e32833832f6].

Acute effects of levosimendan on mitral regurgitation and diastolic function in patients with advanced chronic heart failure

REVERA, MIRIAM;GIGLIO, ALESSIA MAFALDA;DELLA ROSA, FRANCESCO;PARATI, GIANFRANCO
Ultimo
2010

Abstract

BACKGROUND: We analyzed the inodilator properties of levosimendan in patients with chronic heart failure and severe functional mitral regurgitation. METHODS: We studied 20 patients under optimal treatment and in stable clinical condition (New York Heart Association 3.19 ± 0.66; 70 ± 7 years). Levosimendan was infused as a bolus (12 μg/kg in 10 min) followed by a 24-h infusion (0.1-0.2 μg/kg per min). Before and after infusion, Doppler echocardiography, brain natriuretic peptide determination and noninvasive hemodynamic monitoring with bioimpedance cardiography were performed. RESULTS: Levosimendan improved left ventricular ejection fraction (ejection fraction 31 ± 4 from 27 ± 4, P < 0.05), decreased brain natriuretic peptide (333 ± 139 from 629 ± 63 pg/ml, P < 0.01), reduced mitral valve effective regurgitant orifice area to 27 ± 5 from 36 ± 7 mm (P < 0.01) and the velocity of displacement of mitral annulus [ratio between E and E′ waves on Doppler and tissue Doppler (E/E′) from 22.7 ± 1.6 to 13.1 ± 0.6, P < 0.01]. Noninvasive hemodynamic monitoring showed increased acceleration index (a marker of inotropism), and reduced peripheral resistances and thoracic fluid content (P < 0.01). After 4 weeks of washout, some of these effects were still evident. CONCLUSION: In patients with chronic heart failure and functional mitral regurgitation, levosimendan acutely improved systolic and diastolic function, reduced mitral regurgitation and modulated neurohormonal activation, with a tendency for these changes to persist over a short-term follow-up. © 2010 Italian Federation of Cardiology.
Articolo in rivista - Articolo scientifico
advanced chronic heart failure; diastole; functional mitral regurgitation; impedance cardiography; levosimendan; Aged; Cardiography, Impedance; Cardiotonic Agents; Chronic Disease; Diastole; Echocardiography, Doppler; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Italy; Male; Middle Aged; Mitral Valve Insufficiency; Natriuretic Peptide, Brain; Pilot Projects; Pyridazines; Severity of Illness Index; Stroke Volume; Systole; Time Factors; Treatment Outcome; Vasodilator Agents; Ventricular Function, Left; Cardiology and Cardiovascular Medicine
English
2010
11
9
662
668
none
Branzi, G., Malfatto, G., Villani, A., Ciambellotti, F., Revera, M., Giglio, A., et al. (2010). Acute effects of levosimendan on mitral regurgitation and diastolic function in patients with advanced chronic heart failure. JOURNAL OF CARDIOVASCULAR MEDICINE, 11(9), 662-668 [10.2459/JCM.0b013e32833832f6].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/73689
Citazioni
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 14
Social impact